Idogen AB (publ) announces that the company has received approval from the Norwegian REK (Regionale komiteer for medicinsk og helsefaglig forskningetikk) in Oslo to conduct the clinical phase I/IIa study of their drug candidate within the IDO 8 program for patients suffering from hemophilia who have developed antibodies against their life-saving factor VIII treatment. The approval means that study activities can begin at the clinic and that the first patient can be enrolled in the study within short. Idogen has now received approval from the ethics committee in Oslo to conduct the company's phase I/IIa study in hemophilia with the drug candidate, ItolDC-028.

The study is conducted under the leadership of professor and senor physician Pål Andre Holme. Shortly, the first patient will be able to be enrolled, after which the first step in the treatment will be possible to be carried out.